Effect of Fluoroquinolone Resistance on 14-day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy

Which Therapy for Helicobacter pylori Infection?

(2012) David Y. Graham et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

The Efficacy of Second-Line Anti-Helicobacter pyloriTherapy Using an Extended 14-Day Levofloxacin/Amoxicillin/Proton-Pump Inhibitor Treatment - A Pilot Study

(2012) Seng-Kee Chuah et al.   HELICOBACTER

Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection

(2011) Stephan Miehlke et al.   HELICOBACTER

Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults

(2010) Xiaolin Pan et al.   CLINICAL THERAPEUTICS

Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection

(2010) Takahisa Furuta et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

The Evolution of Helicobacter pylori Antibiotics Resistance Over 10 Years in Beijing, China

(2010) Wen Gao et al.   HELICOBACTER

Resistance ofHelicobacter pylorito antibiotics from 2000 to 2009 in Shanghai

(2010) Qin-Juan Sun   WORLD JOURNAL OF GASTROENTEROLOGY

Prevalence of Primary Fluoroquinolone Resistance Among Clinical Isolates ofHelicobacter pyloriat a University Hospital in Southern Taiwan

(2009) Kuei-Hsiang Hung et al.   HELICOBACTER

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication

(2008) S. Di Caro et al.   DIGESTIVE AND LIVER DISEASE